SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a subcutaneous ...
Johnson & Johnson JNJ announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a ...
The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...
The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...
Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...
Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a ...
The FDA approved Tremfya in September 2024 for moderately to severely active ulcerative colitis. The application for moderately to severely active Crohn's disease is currently under FDA review.
Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.
Tremfya (guselkumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as plaque psoriasis. The drug is available as an injection given under the skin or as an IV ...